🔍

Constellation Pharmaceuticals Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Boston, MA USA
Total Funding:$423M
Industry:Pharma
Founded:2008
Lead Investor(s):N/A

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Constellation Pharmaceuticals's estimated annual revenue is currently $27.7M per year.
  • Constellation Pharmaceuticals received $100.0M in venture funding in April 2018.
  • Constellation Pharmaceuticals's estimated revenue per employee is $201,000
  • Constellation Pharmaceuticals's total funding is $423M.

Employee Data

  • Constellation Pharmaceuticals has 138 Employees.
  • Constellation Pharmaceuticals grew their employee count by 27% last year.
  • Constellation Pharmaceuticals currently has 3 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
N/A445N/AN/A-N/A
#2
N/A411N/AN/A-N/A
#3
$43.8M218N/AN/A-N/A
#4
$1737.8M8646N/AN/A-N/A
#5
$26.1M130N/AN/A-N/A
#6
$30.3M38550%N/A-N/A
#7
$5.4M27N/AN/A-N/A
#8
$780.7M3884N/AN/A-N/A
#9
$20.5M102N/AN/A-N/A
#10
$17.3M8648%N/A-N/A
Missing a competitor? Contribute!?
Submit

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.

keywords:Biotechnology,Healthcare,Pharmaceuticals

138

Number of Employees

$27.7M

Revenue (est)

3

Current Jobs

27%

Employee Growth %

$423M

Total Funding

N/A

Valuation

N/A

Accelerator

B2B

Type

Constellation Pharmaceuticals News

09/03/2019 - Analysts Anticipate Constellation Pharmaceuticals Inc (NASDAQ:CNST) to Post -$0.81 EPS

Wall Street analysts expect Constellation Pharmaceuticals Inc (NASDAQ:CNST) to report earnings per share of ($0.81) for the current fiscal ...

09/08/2019 - Constellation Pharmaceuticals to Participate in Two Investor Conferences

CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc. (CNST), a clinical-stage biopharmaceutical ...

09/03/2019 - Constellation Pharmaceuticals, Inc. (:CNST) Buckles Under ...

We see here that Constellation Pharmaceuticals, Inc. (:CNST) is -2.10% away from the 20-Day Simple Moving Average. Their 50-Day Simple ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal FundingOnline ReviewPricing
#1
$37.3M138N/AN/A-N/A
#2
$14.1M138N/AN/A-N/A
#3
$24.8M138N/AN/A-N/A
#4
$20.2M1399%N/A-N/A
#5
$20.2M13932%N/A-N/A

Constellation Pharmaceuticals Funding

DateAmountRoundLead InvestorsReference
2008-04-30$32.0MAThird Rock Ventures, The Column GroupArticle
2010-06-04$22.0MBSR OneArticle
2011-06-07$15.0MBMultipleArticle
2014-08-07$5.0MUndisclosedMultipleArticle
2015-12-11$55.0MUndisclosedArticle
2018-04-10$100.0MUndisclosedMultipleArticle

Constellation Pharmaceuticals Executive Hires

DateNameTitleReference
2009-08-14Mark A. GoldsmithCEOArticle
2009-09-10Edward E. HarlowChief Scientific OfficerArticle
2010-01-11Kerry K. ReinertsenChief Business OfficerArticle
2010-01-21Garen BohlinEVP Finance/OperationsArticle
2011-01-05James E. AudiaChief Scientific OfficerArticle
2011-02-02Michael CooperChief Medical OfficerArticle
2012-03-28Keith E. DionnePresident/CEOArticle
2017-07-19Adrian SenderowiczSVP/Chief Medical OfficerArticle
2017-10-25Emma Reevechief financial officerArticle
2018-11-30Patrick TrojerChief Scientific OfficerArticle
2019-03-05Jessica ChristoChief Product Development OfficerArticle